Navigation Links
NextDocs and Novella to Present on eTMF at DIA 2013
Date:6/19/2013

CONSHOHOCKEN, Pa., June 19, 2013 /PRNewswire/ -- NextDocs announced today that it will co-present with Novella, a full service clinical research organization, at DIA 2013, the Drug Information Association annual meeting and conference.  The companies will present case studies that explore best practices for making the transition from paper trial master file to electronic trial master file (eTMF) systems.

Sharon Ames, enterprise program director at NextDocs will present alongside Krystyna Kowalczyk, executive vice president of clinical operations at Novella, in a session entitled, "That Awkward Stage: Transitioning from Paper Trial Master File to eTMF."  The session will examine how to structure a paper-to-electronic transition that incorporates the needs of ongoing studies while also meeting regulatory needs and reducing operational impacts. 

DIA 2013, the 49th annual meeting and conference of the DIA, is the largest multidisciplinary event for the pharmaceutical and life sciences industry, focusing on advancing therapeutic innovation and regulatory science.  The DIA 2013 conference takes place at the Convention and Exhibition Center in Boston from June 23 - 27, 2013. 

NextDocs and Novella's session, "That Awkward Stage: Transitioning from Paper Trial Master File to eTMF," will take place on Monday, June 24, 2013 at 2:30 p.m.  Additionally, NextDocs will be demonstrating its solutions at the DIA conference in booth #1722.

For more information on DIA 2013, visit www.diahome.org.   For more information on NextDocs, visit www.nextdocs.com.

CONTACT:
Dan Cahill
'/>"/>

SOURCE NextDocs
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NextDocs Expands Customer Roster by More Than 10 Percent
2. NextDocs Launches QuickStart for Emerging Growth Companies
3. NextDocs 6: The New Enterprise Standard for Regulated Content Management
4. NextDocs Corporation Announces Trial Exchange, a Clinical Portal Designed Specifically for Clinical Trial Sites and Integrated with eTMF
5. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Pharma IQ Presents the Latest Trends in Clinical Trial Supply
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
11. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... BOSTON , July 6, 2015 ... Inc. (NASDAQ: ISIS ), announced today that ... Orphan Drug Designation to volanesorsen (ISIS-APOCIII Rx ) ... Syndrome (FCS).  FCS is a rare genetic disease ... of pancreatitis. In a Phase 2 study published ...
(Date:7/5/2015)... 6, 2015 Nihon University is pleased ... on Medical-Engineering Collaboration "Medicine Definitely Jumps Up with ... in Tokyo, Japan . Many ... research will present their achievements and future prospects ... industry produced with 8K technology. (Documentation: ...
(Date:7/3/2015)... 4, 2015 Un fournisseur ... que sont l,hypertension, le diabète et les troubles ... l,intermédiaire de plateformes éducatives gratuites et d,une conférence ... (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ) , ... en ligne , Prendre en charge l,hypertension ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... 23, 2007 -,Gentium S.p.A. (NASDAQ: GENT) (the ... will be the subject of a poster,presentation ... being held in,Rio de Janeiro, Brazil from ... 2007, Cinara Echart, Ph.D., Manager of,Biological Research ...
... 24 /CNW/ - The weight loss medication Xenical,(orlistat ... such as blood pressure, glycaemic,control and lipid profile ... and hypertension, according to a study analysis,presented at ... ,This analysis strengthens the wealth of data already ...
Cached Medicine Technology:Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 2Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 2New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 4New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 5New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 6
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... ... disease prevention in southern California, has partnered with Woodbridge Walk-In Urgent Care to ... cancer, stroke and other serious medical conditions. Screenings are affordable and accurate and ...
(Date:7/6/2015)... , ... July 06, 2015 , ... Seedstock today announced ... keynote address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation and the ... conference , held at the University of California-San Diego, will explore solutions and methodologies ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... & Associates has once again teamed up with Family Emergency Shelter Coalition (FESCO) ... move toward self-sufficiency. FESCO was created especially to provide emergency services and support ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... In a ... learn how to reduce their risk of having a fracture through the bone health ... Fractures Awareness Day. , “We are participating because our residents need this information to ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... in grant funds to support a three-year effort to reduce rates of diabetes ... be conducted in partnership with the Morehouse School of Medicine’s Prevention Research Center ...
Breaking Medicine News(10 mins):Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:National Bone Health Screening and Awareness Day 2Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2
... Millions for Children and Adults with Autism and Other ... ... Safeway is conducting its annual,in-store fundraising and awareness campaign to bring ... Safeway,plans to raise millions of dollars to fund Easter Seals, autism ...
... Inc., the,Midwest,s premier full service egg donor, surrogate, and ... cycle., The Get a Free Egg Donor contest ... of families from all over the world entered and,submitted ... a,free egg donor cycle, a $4,500 value., Frances ...
... Elsevier, the leading publisher of scientific, technical ... that it has added three new modules to ... Procedures Consult ( www.proceduresconsult.com ), which Elsevier ... internal medicine, is an online multimedia resource that ...
... human diseases, researchers must master the details of safe ... of Philadelphia have advanced delivery techniques by creating a ... of gene therapy vectors and can be custom-designed for ... site. , In an animal study, the research team ...
... for 30 minutes during their ... ... National Start! Walking Day. The call to action is simple:,Americans should fit ... Multimedia News Release, go to:, http://www.prnewswire.com/mnr/aha/32529/ Studies reveal that American ...
... i1000SR(R) Analyzer Enhances Workflow and ... Boosts Laboratory ... (NYSE:,ABT) has introduced the ARCHITECT(R) i1000SR(R) immunochemistry analyzer,expanding its ... for labs that typically perform less than,200 immunoassay tests ...
Cached Medicine News:Health News:Safeway's In-Store Disabilities Campaign to Benefit Easter Seals 2Health News:Reproductive Assistance Inc. Gives Back to those Suffering from Infertility 2Health News:Elsevier expands Procedures Consult with emergency medicine, orthopedics and anesthesia procedures 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 3Health News:Video: Start! Walking America: The American Heart Association's National Start! Walking Day Is April 16 2Health News:Video: Start! Walking America: The American Heart Association's National Start! Walking Day Is April 16 3Health News:Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment 2Health News:Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment 3
Inquire...
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The computer-optimized optical design produces large, brilliant images of high resolution....
ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
Medicine Products: